As the COVID-19 pandemic continues evolving, so is access to innovative monoclonal antibody (mAbs) treatments.
On July 27, 2022, the U.S. HHS and Administration for Strategic Preparedness and Response (ASPR) announced they partnered with AstraZeneca to establish an additional pathway for providers to access the COVID-19 mAbs combination known as Evusheld for use with eligible patients.
Read More
